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Chapter
Empiric Antimicrobial Therapy in 
Critically Ill Septic Patients
Ahlem Trifi, Sami Abdellatif, Sameh Trabelsi  
and Salah Ben Lakhal
Abstract
Sepsis is a medical emergency and life-threatening condition due to a  
dysregulated host response to infection, which is time-dependent and associated 
with unacceptably high mortality. At the bedside of a patient with sepsis or septic 
shock, clinician must make immediate life-saving decisions including empirical 
initiation of broad-spectrum antimicrobials; the most likely to be appropriate. 
The empiric regimen should be initiated within the first hour of diagnosis and 
determined by assessing patient and epidemiological risk factors, likely source 
of infection based on presenting signs and symptoms, and severity of illness. 
Optimizing antibiotic use is crucial to ensure successful outcomes and to reduce 
adverse antibiotic effects, as well as preventing drug resistance. All likely patho-
gens involved should be considered to provide an appropriate antibiotic cover-
age. Herein, we tried to make suggestions of empirical therapeutic regimens in 
sepsis/septic shock according to most likely pathogens in cause and sepsis source 
based on the recent recommendations of learned societies. Some suggestions 
were adapted to an environment of low-resource regions where the ecology of 
multi drug resistant organisms is of concern.
Keywords: empiric, antimicrobial, sepsis, septic shock, intensive care
1. Introduction
Sepsis is a clinical syndrome characterized by systemic inflammation due to 
infection (presumed or confirmed). There is a continuum of severity ranging 
from sepsis to septic shock. Diagnosing sepsis remains difficult because it is not 
a single disease but a syndrome with various pathogen and host factor-associated 
symptoms. Sepsis-3 was established to improve risk stratification among patients 
with a suspected infection focusing on organ failures [1]. Sepsis should be 
immediately recognized because it is the primary cause of death from infection, 
especially if not diagnosed and treated promptly. Mortality has been estimated 
to be ≥10 percent and ≥ 40 percent when shock is present [1, 2]. In the United 
States, it is estimated that there are 270 000 deaths a year due to sepsis and 35 000 
deaths attributable to antibiotic resistance [3, 4]. Herein, we discussed the imme-
diate management of sepsis and septic shock mainly the empiric antimicrobials in 
critically ill patients.
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2. Immediate conditioning
Correcting hypoxemia and establishing venous access for the early administra-
tion of fluids and antibiotics are priorities in the management of patients with 
sepsis and septic shock [5, 6].
2.1 Oxygenation
Intubation and mechanical ventilation (MV) may be required to support the 
increased work of breathing that typically accompanies sepsis. Oxygenation should 
be monitored continuously with pulse oximetry. Once MV is indicated, rapid 
sequence intubation (RSI) should incorporates a rapidly acting sedative (ie, induc-
tion) agent, in addition to a neuromuscular blocking (ie, paralytic) agent, to create 
optimal intubating conditions. Then ensure analgesia sedation throughout the dura-
tion necessary for the sepsis/septic shock management while regularly monitoring 
the possibility of weaning from ventilator.
2.2 Venous access
Venous access is essential in the immediate management of sepsis/septic shock. 
The peripheral access has the advantage of the quickness of its putting in (at least 
2 lanes of good caliber). But anyway, we are going to need central venous access. 
Preferably, it is advisable to set up a central venous catheter (CVC) but that should 
not delay the administration of resuscitative fluids and antibiotics. A CVC is useful 
to infuse intravenous fluids, medications (particularly vasopressors) and antibiot-
ics. As well as, it can be used to monitor the central venous pressure (CVP) and the 
central venous saturation (ScvO2).
2.3 Initial investigations
Concomitantly to the initial conditioning including oxygenation and venous 
access, must be carried out: a history with a physical examination of rapid orienta-
tion, biological, microbiological and imaging examinations. This may allows having 
an orientation towards the source and sometimes the pathogen in cause and thus 
guiding the empirical choice of antibiotics.
• Laboratory tests include complete blood counts, Arterial blood gas (ABG), 
analysis of renal and liver functions, D-dimer level, Procalcitonin and serum 
lactate.
• Microbiologic samples include peripheral blood cultures (aerobic and anaero-
bic cultures from at least two different sites), and other samples depending 
of suspect sites should be obtained (e.g., cyto-bacteriologic examination of 
sputum if pneumonia suspected or urine if urinary tract infection evoked, 
catheter tip if catheter-related infection (CRI) evoked, surgical site, etc.). 
Regarding the bloodstream cultures, it is unnecessary to draw blood through a 
catheter, given the risk of contamination by skin flora. The sample should be 
taken from a peripheral venipuncture site.
• Imaging target at the suspected infection site is warranted (eg, chest radiogra-
phy, computed tomography of chest and/or abdomen).
Plea e us  Adobe Acrobat Reader to read this book chapter for free.
Just open this same document with Adobe Reader.
If you do not have it, you can download it here.
You can freely access the chapter at the Web Viewer here.
Securing Connection...Acrobat is locking documen loading.com
r
File cannot be found.
3
Empiric Antimicrobial Therapy in Critically Ill Septic Patients
DOI: http://dx.doi.org/10.5772/intechopen.98327
2.4 Rapid restoration of perfusion (first three hours)
Aggressive administration of intravenous fluids, usually crystalloids given at 
30 ml/kg, started by one hour and completed within the first 3 hours following 
presentation.
Some patients may require higher than recommended volumes, particularly 
those who demonstrate clinical and/or hemodynamic indicators of fluid-respon-
siveness. The clinical and hemodynamic response and the presence or absence 
of pulmonary edema must be assessed before and after each bolus using passive 
leg raising, CVP variation, ScvO2, pulsed pression variation (PPV) or ultrasound 
indicators etc.… Intravenous fluid challenges can be repeated until blood pressure 
and tissue perfusion become acceptable.
2.5 Vasopressors
Vasopressors on CVC if the blood volume is optimized and persistent hypo-
perfusion or immediately if the diastolic blood pressure is less than 40 mmHg.
Based on the SSC (survival sepsis campaign) guidelines 2016 [5], the response 
should be assessed using the following targets within 6 hours: ScvO2 ≥ 70%, 
CVP 8–12 mmHg, mean arterial pressure (MAP) ≥65 mmHg, and urine output 
≥0.5 ml/kg/hour.
3. Empiric antimicrobial therapy (EAT)
Initial selection of particular antimicrobial agents is empiric and is based on an 
assessment of the patient’s underlying host defenses, the potential sources of infec-
tion, and the most likely pathogens depending on the locally epidemiological data. 
EAT is preferably administered within the first hour.
3.1 Times to antibiotics
Once a presumed diagnosis of sepsis or septic shock has been made, optimal 
doses of appropriate intravenous antibiotic therapy should be initiated, prefer-
ably within one hour of presentation and after cultures have been obtained. The 
Infectious Diseases society of America (IDSA) opts to that prompt administration 
of antibiotics is recommended once a presumed diagnosis of sepsis or shock has 
been made by the treating clinician [7]. The Surviving Sepsis Campaign recom-
mends immediate antibiotics for all patients with suspected sepsis and septic shock, 
ideally within 1 hour of recognition.
The literature review does not find a clinical trials evaluating specially the target 
time of one hour to start antimicrobials. That is understandable given the enormous 
ethical concern that results. But almost all observational studies agree that a delay 
exceeding one hour is related to poor outcomes; as well as inadequate doses and 
inappropriate antibiotic therapy [8–14]. Ferrer R, et al. in a large population of 
patients with severe sepsis and septic shock (17,990 patients) demonstrated a linear 
increase in the risk of mortality for each hour delay in antibiotic administration [9]. 
In a retrospective study of 35,000 patients treated in emergency department, the 
increase in absolute mortality associated with an hour’s delay in antibiotic adminis-
tration was 0.3% (p = 0.04) for sepsis, 0.4% (p = 0.02) for severe sepsis, and 1.8% 
(p = 0.001) for shock [11].
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In a large database study comparing patients with sepsis and septic shock treated 
with various types of protocolized treatment bundles (that included fluids and 
antibiotics, blood cultures, and serum lactate) versus those in whom a three-hour 
bundle (blood cultures before broad spectrum antibiotics and serum lactate level) 
was completed within the three-hour time frame [12]. Each 3-hour bundle delay 
achievement increased in-hospital mortality by 1.04 per hour [12]. In addition, 
a delayed completion of a fluid bolus did not increase mortality significantly 
(OR = 1.04) as the delay of antimicrobials [12].
3.2 Identification of suspected source/responsible pathogens
Establishing an accurate diagnosis of the infection site is a priority objective that 
must be fulfilled as soon as possible.
Sometimes the patient arrives with a visible source of infection (e.g. infected 
wound, cellulitis etc). In the case where the source is unclear, the process of its 
identification is based on a good anamnesis for collecting the medical and surgical 
history and a careful and exhaustive physical examination looking for local inflam-
matory signs or function loss. If the source is identified, targeted imaging and 
microbiological sampling should be done and therefore empiric antibiotic therapy 
should be initiated.
In the case where the source remains unclear, it is necessary to complete by an 
exhaustive imaging or even a whole body CT scan and extensive sampling.
Table 1 summarizes the most common sources of infection with a potential risk 
of progress to a sepsis and septic shock and the additional tests to be performed.
Additional diagnostic testing or interventions may be required to identify the 
anatomic site(s) of infection. In particular, in addition to antibiotics, closed space 
infections should be promptly drained or debrided (eg, empyema, abscess) for 
effective source control.
Besides bacteriological examinations, imaging is often essential to recognize 
sites of infection (chest radiography, ultrasound, tomography and MRI).
Sometimes in structures with limited resources, imaging is not always available, 
as are interventional radiology techniques. In this case, blood cultures before the 
administration of antibiotics becomes an essential measure and ideally that should 
be obtained from two sites.
3.3 Regimen to choose
The choice of empirical antibiotic therapy is not a simple attitude and must be 
reasoned upon the presumed primary focus, the history of the patient ((eg, recent 
antibiotics received, previous organisms) and its co-morbidities (eg, diabetes, 
organ failures, immune defect..), invasive devices, nosology (eg, community- or 
hospital-acquired) and the bacterial ecology and resistance patterns of the unit 
where the patient is hospitalized [13, 14, 16–18]. It must be preceded by directed 
bacteriological samples.
Also, the choice of the molecule is made according to its spectrum of action and 
its pharmacodynamics/pharmacokinetics (PK/PD) properties and the spectrum of 
the selected combination must be efficient against gram-positive, gram-negative, 
and anaerobic bacteria because all of these classes of organisms produce similar 
clinical presentations.
Regarding the administration route and dosing, it is recommended that the 
intravenous is mandatory and at high doses to achieve bactericidal serum levels. 
This later correlated with clinical improvement rather than the number of antibiot-
ics prescribed.
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The regimen to choose should consider antipseudomonal in patients with 
neutropenia or burns and anti-anaerobes in intra-abdominal/perineal infections.
Antimicrobial choice should be tailored to each individual. In any case, 
appropriate cultures should be obtained which include two sets of blood cultures 
obtained before antibiotics are started and cultures of other suspected sites of 
infection (sputum, urine, etc.) obtained as soon as possible.




plus exudates ± swelling and 
lymphadenopathy
Throat swab for aerobic culture
Cyto-bacteriological exam of sputum
PCR-SARS CoV2 if pandemic context
Lower respiratory 
tract
Productive cough, pleuritic chest 
pain, consolidative auscultatory 
findings
Sputum of good quality, rapid influenza 
testing, urinary antigen testing (eg, 
pneumococcus, legionella)
PCR-SARS CoV2 if pandemic context





Redness or pus at insertion site Culture of blood (from the catheter and 
a peripheral site), catheter tip bacterial 
exam after removal
Abrasion, wound, 
burn, diabetic foot 
lesion
Erythema, pus, lymphangitis Local swabs gram stain and culture, 
sampling of pus or per cleaning
Skin/soft tissue Lividities, cyanic spots, 
subcutaneous crepitation, local 
hypo- or anesthesia, induration 
exceeding erythema, local necrosis
Culture of flowing liquid or draining 
pus, preoperative tissue samples
Urinary system May differ by gender low 
abdominal pain and vaginal 
discharge in women,
Dysuria, incontinence, cloudy 
urine, prostatic tenderness in men
Vaginal and endocervical sampling 
in women and cytobacteriological 
examination plus culture in both sexes
Deep intra-abdominal 
focus
abdominal pain depending on the 
organ affected, vomiting
Aerobic and anaerobic culture of 
abdominal fluid collections drained 
percutaneously or surgically
Gastrointestinal Diarrhea, vomiting and intestinal 
spasms
Coproculture, parasitological stool 
examination
Meninges and brain Meningitis: stiff neck, sign 
of Kernig and Brudzinski, 
osteotendinous hyper-reflexia
Encephalitis: Altered state of 
consciousness, motor deficit, 
seizures
Lumbar puncture for exhaustive 
examination of the CSF (cytological, 
chemical, bacteriological, search 
for soluble Ag, culture and PCR if 
indicated)
Peritoneal catheter Cloudy fluid, local inflammatory 
signs
Direct examination and culture of the 
discharged fluid
Bones and joints Pain,
Inflammatory signs
MRI, peroperative cultures or by 
interventional radiology
Arthrocentesis, blood cultures
PCR: polymerase chain reaction, SARS CoV2: severe acute respiratory syndrome coronavirus 2, CSF: cerebrospinal 
fluid; PD: peritoneal dialysis; MRI: magnetic resonance imaging.
Source: Reference [15]
Table 1. 
Identification of sources of sepsis and additional tests.
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For most patients with sepsis without shock, antimicrobials may be adminis-
tered in monotherapy or in combination. Anyway, the empiric chosen regimen 
must cover all the maximum number of pathogens most likely involved (ie gram-
positive and gram-negative bacteria, fungi if presence of invasive candidiasis 
factors or immune-compromised for aim Pneumocystis jirovecii, and rarely viruses 
(eg, influenza, Cytomégalovirus (CMV)). For SARS CoV2, all the therapeutic 
means tried so far (chloroquine, macrolides, tocilizumab, remdesivir, monoclonal 
antibody, colchicine ...) are designed for immunomodulatory purposes and no 
treatment is directed specifically against COVID-19.
Patients with septic shock, in whom gram negative bacilli are suspected, must be 
treated with at least two antimicrobials from two different classes according to the 
considered likely organisms and local antibiotic susceptibilities. That is commonly 
called combination therapy defined as more than one antimicrobial agent given in 
the aim to improve efficiency against a known or suspected pathogen.
Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, and Streptococcus 
pneumoniae, are the most common isolated organisms from patients with sepsis. 
Thus, these organisms should be taken into account when choosing empiric regi-
men [19]. Betalactams such carbapenem, piperacillin-tazobactam, in combination 
or not with aminosides or quinolones are a good alternative to cover a large batch of 
gram negative and positive organisms.
When nosocomial nature of sepsis or septic shock is suspected, the multire-
sistant profile of microorganisms (mainly non fermenting gram negative bacilli 
including Acinetobacter Baumannii) should be covered [20, 21].
Otherwise, the following pathogens must be included in the spectrum of antibi-
otics to be chosen and this according to the risk factors for their presence:
• Methicillin-resistant S. aureus: Today, methicillin-resistant S. aureus (MRSA) 
is no longer classified among the pathogens of healthcare-related infections 
since it is increasingly described in community infections [22, 23]. That is 
why empirical intravenous vancomycin (be careful with the doses if renal 
impairement) should be added in subjects with sepsis/septic shock at risk of 
MRSA. Linezolid if MRSA refractory (VISA or GISA of susceptibility profile) 
or a contraindication to vancomycin can also be suggested as an anti MRSA. 
Daptomycin may be prescribed in cases of extra-pulmonary MRSA infection. 
In skin and soft structures infections, IDSA update 2014 proposed vacomycin, 
linezolid, clindamycin, daptomycin and ceftaroline/fosamil may be proposed.
• Pseudomonas aeruginosa: if Pseudomonas is a likely pathogen and depending 
on local antibiotic susceptibility patterns, antimicrobials proposed are:
 ○ Antipseudomonal cephalosporin (eg, ceftazidime, cefepime), or
 ○ Antipseudomonal carbapenem (eg, imipenem, meropenem), or
 ○ Antipseudomonal beta-lactam/beta-lactamase inhibitor (eg, piperacillin-
tazobactam, or Fluoroquinolone with good anti-pseudomonal activity 
(eg, ciprofloxacin), or Aminoglycoside (eg, gentamicin, amikacin), or 
Monobactam (eg, aztreonam)
• Enterobacteria (eg, E. coli, K. pneumonia, Proteus, Providencia, Serratia): 
They are pathogens treated, for a long time, by a regimen which combines 
several antibiotics although this is not proven by studies. Indeed, in the old 
meta-analysis of Safdar N, et al. the summary odds ratio was 0·96 (95% CI 
Plea e us  Adobe Acrobat Reader to read this book chapter for free.
Just open this same document with Adobe Reader.
If you do not have it, you can download it here.
You can freely access the chapter at the Web Viewer here.
Securing Connection...Acrobat is locking documen loading.com
r
File cannot be found.
7
Empiric Antimicrobial Therapy in Critically Ill Septic Patients
DOI: http://dx.doi.org/10.5772/intechopen.98327
0,70–1,32), indicating no mortality benefit with combination therapy com-
pared to monotherapy with a third generation cephalosporin or a carbapenem 
[24]. Furthermore, the combination to an amino-glycoside was related to an 
increase of nephrotoxicity [24].
Therefore, it is recommended to administer a single antimicrobial agent known 
to have proven efficacy and the least possible toxicity. Patients with neutro-
penia or in whom Pseudomonas is suspected are to exclude from this rule and 
combination therpay should be contemplated.
• Carbapenemase-producing Enterobacteriaceae (CPE) are becoming an 
emerging concern worldwide. Infections caused by these pathogens are 
associated with high morbidity, mortality and costs while they are difficult 
to treat since only a small number of therapeutic options are available. Only a 
few clinical studies, often size-limited and retrospective, have been conducted 
mainly on infections caused by KPC - producing Klebsiella pneumoniae whereas 
there are more in vitro and animal data. In some cases, β-lactams can be used, 
such as carbapenems (if MIC ≤8 mg/L), aztreonam or ceftazidime. A double-
carbapenem regimen also seems to be promising, with ertapenem. Polymyxins 
and tigecyline (with a loading dose and high dosages) are possible alternatives 
in combination. Aminoglycosides (especially gentamicin) in monotherapy are 
choice options for the treatment of urinary tract infections. Fosfomycin may 
be used in combination but there is a risk of emergence of resistant mutants 
during therapy. For the treatment of severe infections (bacteremia and pneu-
monia), combination therapy should be used since risks of clinical failure 
and mortality are significantly lower than with monotherapies in the majority 
of studies. The most frequent combinations are polymyxins-carbapenems, 
tigecycline-carbapenems and polymyxins-tigecycline, knowing that carbape-
nem-based regimens (if MIC ≤8 mg/L) must be favored [25].
Acinetobacter Baumannii: Acinetobacter are opportunistic and ubiquitous 
bacteria that occur in the form of Gram-negative coccobacilli. Among the 
species of this genus, Acinetobacter baumannii is the most implicated in noso-
comial infections, especially in ICU [26]. This bacterium is involved in a wide 
range of infections such as VAP, bacteremia, CRI, urinary tract infections, 
secondary wound infections or postoperative meningitis.
A.baumannii exhibits a remarkable ability to acquire mechanisms of resistance 
to antibiotics, rapidly leading to multi-resistance to almost all commercially 
available antibiotics and sometimes to therapeutic dead ends [27].
Acinetobacter baumannii is one of the ESCAPE organisms (Enterococcus fae-
cium, Staphylococcus aureus, Clostridium difficile, Pseudomonas aeruginosa, and 
Enterobacteriaceae), a group of clinically important, predominantly health 
care-associated organisms that have the potential for substantial antimicrobial 
resistance [28].
Independent risk factors for colonization or infection with resistant strains of 
Acinetobacter include the following [29–32]: prior colonization with MRSA, prior 
beta-lactam (particularly carbapenems) or fluoroquinolone use, bedridden status, 
current or prior ICU admission, presence of a CVC, recent surgery, Mechanical 
ventilation, Hemodialysis, malignancy, steroids therapy.
Empiric antibiotic therapy for Acinetobacter, before results of antimicrobial 
susceptibility testing are available, should be selected based on local susceptibil-
ity patterns. In general, it should consist of a broad spectrum cephalosporin, a 
combination beta-lactam/beta-lactamase inhibitor (eg, a combination including 
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sulbactam), or a carbapenem. An additional agent may be warranted if local resis-
tance rates to the chosen antibiotic class are high (eg, greater than 10 to 15%).
When rates of resistance to the selected antimicrobial agent are low (ie, below 10 
to 15 percent), monotherapy is likely adequate as there are no data to clearly dem-
onstrate that combination therapy improves outcomes through synergistic effect. 
However, when rates of resistance are higher, it is reasonable to use one of the 
agents above in combination with an antipseudomonal fluoroquinolone, an amino-
glycoside, or colistin to improve the likelihood of administering an antibiotic agent 
that retains activity. While there are no clear clinical data to support this practice for 
Acinetobacter infections, many experts favor empiric combination therapy for seri-
ous infections with these and other potentially resistant gram-negative organisms 
because of the increased mortality associated with inappropriate empiric therapy.
A prospective cohort study was made in 70 ICU patients with nosocomial sepsis/
septic shock in whom imipenem/colistin was prescribed as first line antibiotic 
therapy [33]. The main findings were: this regimen was only appropriate in 52% of 
cases and inappropriateness was associated with an increased ICU mortality risk 
(OR = 6.27, 95% CI [1.83–21], p = 0.003) [33].
• If isolates susceptible to first line agents: we favor choosing the agent with the 
narrowest spectrum of activity. Other considerations in selection of a regimen 
include patient drug allergies or intolerance; need to cover additional  
infections, and hospital formulary.
• If resistant isolates: in the setting of resistance to first line agents, therapeutic 
options are generally limited to polymyxins (colistin [polymyxin E] and poly-
myxin B), and tigecycline. We generally use polymyxins, for which there is the 
most clinical experience in treating extensively drug-resistant Acinetobacter.
Susceptibility testing for these agents should be performed as well prior to their 
use given the possibility of resistance.
We generally favor using a second agent, such as a carbapenem, tigecycline, or 
rifampin, in addition to polymyxins for serious infections (eg, bacteremia, pneu-
monia, critical illness) with resistant isolates.
There are no definitive clinical data that demonstrate improved outcomes with 
combination versus monotherapy, and some randomized trials have suggested that 
certain combinations (colistin and rifampin or colistin and meropenem or fosfo-
mycin) resulted in comparable clinical outcomes as monotherapy with colistin [34, 
35]. Nevertheless, infections with multidrug-resistant Acinetobacter are associated 
with high mortality rates, and we are concerned that the use of a single agent is 
not adequate, particularly since resistance can develop during therapy, leaving no 
therapeutic alternatives. The synergistic pharmacological tests are a great contribu-
tion to the choice of treatment and consultation with an expert in the management 
of such infections is advised.
In case of ventilator acquired pneumonia (VAP) caused by Acinetobacter, addi-
tional considerations include the possible use of adjunctive inhaled antibiotics. 
Inhaled colistin may be beneficial in select patients [36–38], although not all studies 
suggest a benefit [39]. We favor use of inhaled colistin among patients with severe 
pneumonia due to Acinetobacter only sensitive to colistin, since intravenous colistin 
yields low lung concentration. The optimal dose of inhaled colistin is uncertain 
and ranges from 75 to 150 mg colistin base activity (2.25 to 4.5 million international 
units CMS) twice daily. Higher doses, up to 5 million international units colisti-
methate sodium (approximately 167 mg colistin base) every eight hours, have also 
been used for VAP with Acinetobacter [40].
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• Invasive fungal infections: Fungal infections are a feared complication in ICU 
patients. Their epidemiology has deeply changed linked to major changes in 
medical practices (induced immunosuppression, organ transplants, cytotoxic 
chemotherapy, ICU invasive procedures, parenteral nutrition, and prolonged anti-
microbial). Moreover, several factors depend on patient’s morbidities (chronic liver 
or renal failure, diabetes, surgery, septic shock or multisite Candida colonization).
The Arsenal antifungal therapy has also broadened considerably with new 
molecules, such echinocandins, well tolerated than amphotericin B. The use of 
an empiric antifungal in patients exhibiting sepsis and septic shock has been 
widely debated with a rather converging towards the absence of a favorable 
effect on mortality [41–44]:
Cortegiani A, et al. in a meta-analysis including 22 studies (total of 2761 par-
ticipants) concluded that the use of untargeted antifungal is not associated with a 
significant reduction in all-cause mortality and may be associated with a reduction 
of invasive fungal infection among ICU patients [41]. Empiric antifungal treatment 
(mostly fluconazole) not decreased risk of mortality or occurrence of invasive 
candidiasis in ICU patients receiving mechanical ventilation for at least five days 
[42]. In addition, the multicenter randomized trial conducted in ICU (known as 
EMPIRICUS, n = 260 patients colonized with Candida and having sepsis), micafun-
gin administered for 14 days did not improve 28 day-survival without infection [43].
In a 8-years retrospective double cohort (empiric antifungal group, n = 125 
versus no empiric antifungal group, n = 122), no improvement of 28-day survival 
was found. Moreover, no preventing effect on a new episode of candidemia. 
Nevertheless, a beneficial effect of empiric antifungal on survival was found in 
patients with an Acute Physiology and Chronic Health (APACHE) II score < 16: 
OR = 0.68; CI 95% [0.53–0.87]; p = 0.002 [44]. That means; it is the less severe 
patients who can benefit from an empiric fungal.
However, if Candida or Aspergillus is strongly suspected or if neutropenia is present, 
echinocandin (for Candida) or voriconazole (for Aspergillus) are often appropriate [45].
Even if our focus here is the empirical choice of antibiotic therapy in septic 
ICU patients, but it would be wise to suggest a list of the more common potential 
pathogens that would need to be treated. The main pathogens to be considered in 
community infections depending on the infected site are:
Community acquired pneumonia (CAP): Streptococcus pneumoniae, 
Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophyla, 
Haemophilus influenzae, Enterobacteria, anaerobies, Staphylococcus aureus.
Community meningitides: Streptococcus pneumoniae, Nesseria meningitis, 
Listeria monocytogenes Haemophilus influenzae, Enterobacteria, Streptococcus sp.
Urinary tract infections: Escherichia coli, Proteus mirabilis, Klebsiella pneu-
moniae, Staphylococcus saprophyticus, Enterobacter sp, Enterococcus sp.
Skin and soft tissues infections: Streptococcus pyogenes, Staphylococcus aureus, 
anaerobies.
Intrabdominal infections: Escherichia coli, Klebsiella pneumonia, anaerobies 
(Bacteroides fragilis) Enterobacter sp, Enterococcus sp, Streptococcus pneumoniae, 
Pseudomonas sp.
For nosocomial infections, Gram-negative bacilli are mostly involved followed 
by Gram-positive cocci. The main multidrug-resistant bacteria (MDRs) to be con-
sidered are: Methicillin-resistant Staphylococcus aureus (MRSA), Enterobacteriaceae 
producing Extended spectrum beta-lactamases (ESBL) or hyperproducing cepha-
losporinases (HPCase), Pseudomonas æruginosa, Acinetobacter Baumannii and 
Enterococci Vancomycin Resistant (EVR).
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Suspected source of sepsis/
septic shock
Unknown Source (includes 
catheter related blood stream 
infection)
Vancomycin* PLUS Cefepime 1 g/6H or Aztreonam 2 g/8H or imipenem 
1 g/ 8H (if known high incidence of MDR GNB in the unit) +/− 
Tobramycin 7 mg/kg IV EIAD+
+ Consider addition of antifungal in those at high risk for candidemia 
(caspofungine 70 mg followed by 50 mg daily or anidulafungine 200 mg 
the 1st day relayed by 100 mg daily or micafungin 100 mg daily).
Intra-abdominal Source Piperacillin/tazobactam 4 g/6H OR Ertapenem 1 g/d
OR Aztreonam 2 g/8 h OR Cefepime 1 g/6H (failing cefotaxime 1 g/4H) 
PLUS Metronidazole 500 mg/8H +/− Gentamicin 5–7 mg/kg IV (adjust 
the dosing with dosage of the max and residual concentration +)
Urinary Tract Cefotaxime 1 g/6H or Ceftriaxone 2 g daily +/− Gentamicin 7 mg/kg
If History ESBL colonization: Ertapenem 1 g/d OR
Aztreonam 2 g/8 h PLUS Gentamicin 7 mg/kg
If history of MDR pathogen or Pseudomonas: Imipenem 1 g/8H PLUS 
Amikacine 25 mg/Kg/d
Skin/Soft Tissue Infection:
Necrotizing Skin/Soft Tissue: 
Gas Gangrene or Necrotizing 
Fasciitis
If MRSA not suspected: Piperacillin/tazobactam 4 g/ 6H PLUS 
gentamycin 5–7 mg/Kg EIAD
+/−
Clindamycin 900 mg/8H (only if toxic shock present)
If MRSA suspected:
Vancomycin 30 mg/kg/d in 2 divided doses*
+/− Clindamycin 900 mg/8H
OR Linezolid 600 mg/12H OR Ceftaroline 600 mg/12H
Severe CAP Ceftriaxone 2 g/24 h PLUS Levofloxacin 500 mg/ 12 h OR 
Azithromycin 500 mg /24 h
Severe beta-lactam allergy: only Levofloxacin 500 mg /24H and Consider 
addition of vancomycin OR Linezolid 6oo mg/12H if MRSA is suspected 
(CT features+)
Severe CAP with the following 
Risk factors:
⁮Hospitalized ≥5 d in the past 
90 days
⁮Broad spectrum or IV 
antimicrobial for ≥5 days in the 
past 90 days
⁮Known respiratory tract 
colonization with an MDR 
organism
⁮Residence in a long-term care 
facility
Imipenem 1 g/8H OR Piperacillin/tazobactam 4 g/6H OR Cefepime 
1 g/6 h
PLUS Azithromycin 500 mg/24 h
+/− Vancomycin IV or Linezolide 600 mg/12H if MRSA suspected





⁮Broad spectrum or IV 
antimicrobial for ≥5 days in the 
past 90 days
⁮Known respiratory 
colonization with an MDR 
organism
⁮Septic shock
Imipenem 1 g/8H OR Meropenem 1 g/8 h OR Aztreonam 2 g/ 6 h
PLUS Colistin 9MU in loading dose relayed by 4,5 MU /12H +/− 
Vancomycin (if MRSA suspected)
Consider adjunction of inhaled colistin if high incidence Acinetobacter 
only susceptible to colistin
*Vancomycin dosed per pharmacy consult. Typically with loaded with 20–25 mg/kg dose initially (max 2 g initial 
dose).
MDR GNB: multi drug resistant gram negative bacilli, ESBL: Extended spectrum betalactamases, MRSA: 
Methicillin-resistant Staphylococcus aureus, CAP: Community Acquired Pneumonia, HCAP: healthcare acquired 
pneumonia, HAP: hospital acquired pneumonia, VAP: ventilator acquired pneumonia.
Table 2. 
Suggested regimens for empiric antimicrobials in sepsis/septic shock.
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Table 2 displays suggested regimens for empiric antimicrobials in sepsis and 
septic shock according to the suspected Source (all antibiotics are to be adminis-
tered intravenously).
3.4 Dosing and modality of administration
Maximizing the dose in patients with sepsis and septic shock is a judicious atti-
tude. This strategy is based upon the known increased volume of distribution that 
can occur in patients with sepsis due to the administration of fluid and the action 
of inflammatory cytokines [46, 47] and that higher clinical success rates have been 
reported in patients with higher peak concentrations of antimicrobials [48, 49]. 
Continuous infusions of antibiotics as compared with intermittent dosing regimens 
remain investigational at this time [50].
The meta-analysis of Chen CH, et al. [51] (9 RCTs plus 4 retrospective studies, 
1957 participants) compared continuous and intermittent groups. A significant dif-
ference was showed with mortality which was higher in the subgroup of continuous 
infusion (OR 1.433, 95% CI: 1.139–1.801). In this same group, length of stay in ICU 
was shorter and antibiotic duration was longer but without significance [(OR 0.834, 
95% CI: 0.542–1.282) and (OR 1.055, 95% CI: 0.659–1.689) respectively] [51].
However, authors were unable to recommend continuous infusion of intra-
venous antibiotics better than traditional intermittent infusions of antibiotics at 
routine clinical care.
In general, the choice of the administration modality depends above all on the 
PK/PD characteristics of the antibiotic. Time-dependent antibiotics (eg betalac-
tamins, vancomycin) their bactericide are based on the time of contact with the 
Antimicrobial Dose
Imipenem-cilastatin 0.5 to 1 g intravenously every 6 hours to 1 g every 8 hours
Meropenem 1 to 2 g intravenously every 8 hours
Doripenem 0.5 g intravenously every 8 hours
Gentamicin¶ 1 to 2.5 mg/kg intravenously every 8 to 12 hours or 7 mg/kg every 24 to 48 hours 
depending on creatinine clearance
Tobramycin¶ 1 to 2.5 mg/kg intravenously every 8 to 12 hours or 7 mg/kg every 24 to 48 hours 
depending on creatinine clearance
Amikacin¶ 5 to 7.5 mg/kg intravenously every 8 hours or 15 mg/kg every 24 to 48 hours 
depending on creatinine clearance
Ciprofloxacin¶ 400 mg intravenously every 8 hours
ColistinΔ 2.5 to 5 mg/kg/day as colistin baseΔ intravenously in two to four divided doses
Polymyxin B 25,000 units/kg (2.5 mg/kg) loading dose followed by 12,500 units/kg  
(1.25 mg/kg) intravenously every 12 hours
Minocycline 200 mg single dose, followed by 100 mg intravenously every 12 hours
Tigecycline◊ 100 mg single dose, followed by 50 mg intravenously every 12 hours; 100 mg every 
12 hours in serious infections
¶Aminoglycosides and fluoroquinolones are generally used in combination with another agent.
Source: Reference [52, 53]
Δmeans that the recommended dosage corresponds to that of colistin base, the conversion is: 1 mg colistin base = 
2.67 mg colistimethate = 33.3 IU. Thus 2.5 to 5 mg / kg / day of colistin base correspondsabout 6 to 12 million IU of 
colistimethate.
◊For severe hepatic dysfunction: loading dose is the same (100 mg) followed by 25 mg IV every 12 hours.
Table 3. 
Dosage of most common prescribed systemic antibiotics in ICU adults with normal renal function.
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microorganism at doses above the MIC. Therefore the administration of this type of 
antibiotic in continuous infusion or in multiple doses is preferred. On the other hand, 
dose-dependent antibiotics (eg aminosia, colistin), whose effectiveness depends 
on the peak concentration reached, their administration at a single or twice dose is 
preferred.
Dosing of the most common prescribed antimicrobials in ICU patients with 
normal renal function is summarized in the Table 3. When renal function impair, 
antibiotic’s doses should be adjusted according to the creatinine clearance.
The follow up of infection’s indices is mandatory, including complete blood 
count and additional cultures. Results should prompt modification of antibiotic 
choice if a better and safer regimen can be substituted and/or investigations 
directed towards source control.
3.5 Eradication of septic focus
It should be undertaken in timely manner when they feasible since undrained 
foci of infection may not respond to antibiotics alone. Typical examples are: 
infected catheter which must be removed (obviously after the establishment of 
another vascular access), plumonary abscess and chest wall, obstructive pyelone-
phritis which indicates percutaneous nephrostomy, cholecystectomy, peritonitis to 
be cleaned in the operative room, dermo-hypoderma which require debridement or 
amputation of soft tissues, etc.
Expert opinions recommend not exceeding 6 to 12 hours since the identification 
of septic focus and its eradication in order to facilitate access to antibiotics and thus 
improve survival.
3.6 De-escalation and duration of antibiotics
Antibiotics started for sepsis should be reassessed daily for potential discontinu-
ing if sepsis is ruled out or narrowing if more data becomes available [54]. While 
there is no consensus on de-escalation criteria, most experts use follow-up clinical 
(improved vital signs), laboratory and imaging data, and a fixed course of broad-
spectrum therapy (eg, 3 to 5 days). After culture and susceptibility results return 
and/or after patients clinically improve, antimicrobial therapy may be narrowed 
to a few days. When possible, antimicrobial therapy should also be pathogen/
susceptibility-directed. However, since no pathogen is identified (almost in 50% of 
patients), de-escalation of empiric therapy requires a component of clinical judg-
ment. For example, vancomycin is typically discontinued, if no Staphylococcus is 
cultured.
Concerning the duration of antibiotic therapy, it must be reasoned and reas-
sessed on a case-by-case basis. Often duration of 7 to 10 days is sufficient [55]. 
For certain cases, this duration must be prolonged up to even three weeks (mainly 
septicaemic presentations with metastatic locations (endocarditis, osteomyelitis, 
large abscess), a lack of clinical improvement within the usual timeframes, deep 
infections with Candida or aspergillus, some viral infections (Herpes or cytomega-
lovirus), isolation of extensively drug resistant (XDR) Gram-negative bacilli, 
immune disorders [56].
3.7 Role of procalcitonin
PCT appears to be a more relevant marker in diagnostic for bacterial infections. 
Its serum level increases in case of severe bacterial or parasitic infection with a 
sensitivity comparable to that of PCR but with better specificity. The importance 
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of its serum level at the time of initial treatment would be also correlated with a 
subsequent poor prognosis of patients.
Although many institutions and guidelines support the use of procalcitonin to 
limit antibiotic (empiric or therapeutic) use in critically ill patients with suspected 
infection or documented infection, the evidence to support this practice is limited. 
Other studies suggest that procalcitonin may distinguish infectious from noninfec-
tious conditions and may therefore facilitate the decision to de-escalate empiric 
therapy [57, 58].
In addition, studies of the kinetics of PCT were more interesting and useful than 
studies of a static value of unadjusted PCT. MDT is a favorable marker to assess 
changes in clinical symptoms and patient prognosis. MDT may improve the judg-
ment of disease severity in patients with sepsis or septic shock, thereby improving 
the ability of clinicians to accurately assess disease prognosis [59]. Hence, we 
suggest that PCT be assessed daily or at default every 48 hours for critical septic 
patients.
4. Conclusions
For patients with sepsis, we opt to an optimal doses of empiric broad spectrum 
intravenous therapy with one or more antimicrobials be administered, in a prompt 
fashion (eg, within one hour) of clinical presentation. For patients with septic 
shock with likely gram negative sepsis we suggest combination therapy (at least 
two) from different classes given with the intent of covering a known or suspected 
pathogen with more than one antibiotic. It is the only guarantor for sufficient 
activity to cover a broad range of gram negative and positive organisms and, if sus-
pected, against fungi and viruses. Agent selection depends upon patient’s history, co 
morbidities, immune defects, clinical context, suspected site of infection, presence 
of invasive devices, and local prevalence and resistance patterns.
The advent of new technologies (multiplex-PCR) with the ability to type and 
characterize microorganisms without the need for conventional culture techniques 
may negate the requirement for highly specialized microbiology staff and facilities. 
These methods could eventually contribute significantly to improved management 
of patients with sepsis and septic shock as well as antibiotic stewardship programs.
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